Additional Study Information: The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will find out if XmAb22841 works in treating tumors like the one that you have and will help researchers identify the side effects that occur from taking XmAb22841 alone and in combination with pembrolizumab. XmAb22841 is an investigational drug that is designed to activate your own cells to kill your tumor. Solid tumors include: bladder cancer, breast cancer, kidney cancer, adrenal cancer, lung cancer, cervical cancer, pancreatic cancer, colon cancer, rectal cancer, liver cancer, and melanoma.